Jcar-017 Cd19-Specific Chimeric Antigen Receptor
B-Cell Chronic Lymphocytic Leukemia
Explore 67 assets in B-Cell Chronic Lymphocytic Leukemia →Floatz Rating
B61/100
Confidence
Indicative
Sponsor
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Modality
Cell therapy
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
51Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06205290CT.gov A Study to Compare the Efficacy and Safety of Lisocabtagene Maraleucel vs Investigator's Choice Options in Adult Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, Whose Disease Has Failed Treatment With Both BTKi and BCL2i Therapies | — | Withdrawn | — | — | — |
NCT06357754CT.gov Transgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufactured Gene Modified Cell Therapy and Have a Qualifying Second Primary Malignancy | — | Recruiting | — | — | — |
NCT03331198CT.gov Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · B-Cell Chronic Lymphocytic Leukemia
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Jcar-017 Cd19-Specific Chimeric Antigen Receptor (this asset) | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | P3 | B · 61 |
| Humax-Cd20 | Emory University | P4 | BBB |
| Fludarabine | Ohio State University Comprehensive Cancer Center | P4 | BBB |
| Acalabrutinib | Zulfa Omer | P4 | BBB |
| Rituximab | Zulfa Omer | P4 | BBB |
| Cyclophosphamide | Ohio State University Comprehensive Cancer Center | P4 | BBB |
| Obinutuzumab | Paolo Caimi, MD | P3 | BB |
| Cediranib | City of Hope Medical Center | P2 | BB |
| Ibrutinib | Janssen Research & Development, LLC | P4 | BB |
+42 more in the B-Cell Chronic Lymphocytic Leukemia cohort
Other indications for Jcar-017 Cd19-Specific Chimeric Antigen Receptor
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Diffuse Large B-Cell Lymphoma | — | P3 | BB · 66 |
| Primary Mediastinal Large B-Cell Lymphoma | — | P2 | BB · 65 |
| Non-Hodgkin Lymphoma | — | P3 | BB · 65 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Jcar-017 Cd19-Specific Chimeric Antigen Receptor in B-Cell Chronic Lymphocytic Leukemia. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/jcar-017-cd19-specific-chimeric-antigen-receptor-b-cell-chronic-lymphocytic-leukemia
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →